Medical Centre Synexus Sofia EOOD

Running trials

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Source

• Recruiting

  An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

  NCT04638647· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ankylosing spondylitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

  2024-512417-41-00· Phase 3· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Completed

  A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.

  2022-502778-18-00· Phase 3· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Source

• Active, not recruiting

  THIO Sequenced With Cemiplimab in Advanced NSCLC

  NCT05208944· Phase 2· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· Source

• Completed

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· Phase 3· Source

• Completed

  Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

  NCT03164928· Phase 3· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source